PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
33399495-12	2021	CONCLUSIONS: Red-A overcomes immuno-resistance of NSCLCs to NK cells by down-regulating CD155 expression, which shows the possibility of developing checkpoint inhibitors targeting TIGIT/CD155 signalling to overcome immuno-resistance of cancer cells.	rediocide A	13-18	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	180-185
34992684-3	2022	Binding of T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) among other immune checkpoints on natural killer (NK) and T cells to CD155/CD112 in tumors is supposed to be inhibitory; however, the mechanism by which changes in CD155 and CD112 expression affect tumor immunity remains unclear.	Tyrosine	52-60	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	92-97
34625514-5	2021	RESULTS: The results of both TCGA and validation data suggested that high expression of programmed cell death 1 ligand 1 (PD-L1), T-cell immunoglobulin and mucin-domain-containing-3 (TIM3), and T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) was associated with poor overall survival (OS) of patients with ESCC.	Tyrosine	235-243	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	275-280
34694361-1	2021	The co-stimulatory and co-inhibitory immunoreceptors DNAX accessory molecule-1 (DNAM-1) and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) are paired activating and inhibitory receptors on T cells and natural killer (NK) cells.	Tyrosine	153-161	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	194-199
34853812-10	2021	The immunosuppression markers including PDCD1, TIGIT, LAG3, and HAVCR2 were significantly upregulated in the T cells bearing a high glucose uptake signature score.	Glucose	132-139	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	47-52
34707863-3	2021	As CMV infection modifies natural killer (NK) cell properties and NK cells contribute to protection against HIV-1 infection, we considered the role of T-cell immunoreceptor with immunoglobulin and intracellular tyrosine inhibitory motif domains (TIGIT) in NK cell-based HIV-1 immunotherapy and elimination strategies.	Tyrosine	211-219	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	246-251
34097428-7	2021	Furthermore, patients with HER2+ tumors were more likely to have increased TIM-3 expression on CD8+ T cells (p = 0.043), whereas patients with a better response to NAC were more likely to express TIGIT on CD8+ T (p = 0.014) and CD16- CD56bright NK cells (p = 0.003), respectively.	nac	164-167	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	196-201
34659197-1	2021	T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is an immunosuppressive receptor expressed on the surface of immune cells, suppressing immune responses by activating the intracellular negative regulatory signals.	Tyrosine	41-49	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	81-86
34659197-6	2021	In the in vitro co-culture assays of T cells and tumor cells, the suppressed glucose metabolic activity of T cells was reversed by TIGIT blockade.	Glucose	77-84	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	131-136
35590334-7	2022	In addition, we observed remarkable enhancement of multiple inhibitory receptors (TIGIT, PD-1, TIM-3, CD38, CD39) on both CD4+ and CD8+ T cells on day 30 post-transplantation in patients who received PTCy.	ptcy	200-204	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	82-87
34105506-1	2021	TIGIT is an inhibitory receptor containing T cell immunoglobulin and immune receptor protein tyrosine inhibitory motif domain.	Tyrosine	93-101	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	0-5
34068552-0	2021	Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPalpha and TIGIT/PVR Pathways for Cancer Immuno-Therapy.	azelnidipine	14-26	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	76-81
34068552-7	2021	Azelnidipine was found to dual block CD47/SIRPalpha and TIGIT/PVR pathways by co-targeting SIRPalpha and PVR.	azelnidipine	0-12	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	56-61
35090381-4	2022	We developed an IgG4-type monoclonal antibody against human TIGIT, designated as MG1131, using a phage display library of single-chain variable fragments (scFvs).	mg1131	81-87	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	60-65
35039625-9	2022	CONCLUSIONS: TIGIT/PD-1-based risk stratification with distinct immune and molecular features could be served as a predictor for systematic therapeutic response including adjuvant chemotherapy and immunotherapy in MIBC patients.	4-METHYL-2-PENTANOL	214-218	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	13-18
35467979-3	2022	Computational, preclinical, and patient tumor multiplexed analyses revealed that tumor-associated focal adhesion kinase (FAK) activation regulates CD155 expression, a checkpoint ligand for TIGIT (T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains).	Tyrosine	257-265	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	189-194
35379324-15	2022	Furthermore, physical activity inhibited Treg cell infiltration and immune checkpoint expression (including CTLA4, TIGIT and TIM3) induced by long-term combined lenvatinib plus anti-PD-1 therapy, improving efficacy.	lenvatinib	161-171	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	115-120
35265633-2	2021	An immunosuppressive receptor, T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is specifically expressed in NK cells.	Tyrosine	72-80	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	119-124
35273697-3	2022	Recently, T cell immunoglobulin and immune receptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) have been identified as coinhibitory receptors, similar to PD-1.	Tyrosine	52-60	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	99-104
35465350-7	2022	Stt and Tcz induce a decrease in STAT-3 phosphorylation in the DU145 cells and, in turn, induce an increase of NKp46 and a decrease of TIGIT expression in NK-92 cells.	stattic	0-3	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	135-140
35236323-10	2022	The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher  IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + .	Cisplatin	189-198	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	282-287
35236323-10	2022	The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher  IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + .	Doxorubicin	214-225	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	282-287
35090381-5	2022	MG1131 interacts with TIGIT much more tightly than PVR does.	mg1131	0-6	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	22-27
35090381-6	2022	The crystal structure of a scFv version of MG1131 bound to TIGIT was determined, showing that MG1131 could block the PVR-TIGIT interaction and thus the immunosuppressive signaling of TIGIT.	mg1131	43-49	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	59-64
35090381-6	2022	The crystal structure of a scFv version of MG1131 bound to TIGIT was determined, showing that MG1131 could block the PVR-TIGIT interaction and thus the immunosuppressive signaling of TIGIT.	mg1131	43-49	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	121-126
35090381-6	2022	The crystal structure of a scFv version of MG1131 bound to TIGIT was determined, showing that MG1131 could block the PVR-TIGIT interaction and thus the immunosuppressive signaling of TIGIT.	mg1131	43-49	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	183-188
35090381-6	2022	The crystal structure of a scFv version of MG1131 bound to TIGIT was determined, showing that MG1131 could block the PVR-TIGIT interaction and thus the immunosuppressive signaling of TIGIT.	mg1131	94-100	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	59-64
35090381-6	2022	The crystal structure of a scFv version of MG1131 bound to TIGIT was determined, showing that MG1131 could block the PVR-TIGIT interaction and thus the immunosuppressive signaling of TIGIT.	mg1131	94-100	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	121-126
35090381-6	2022	The crystal structure of a scFv version of MG1131 bound to TIGIT was determined, showing that MG1131 could block the PVR-TIGIT interaction and thus the immunosuppressive signaling of TIGIT.	mg1131	94-100	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	183-188
35090381-7	2022	Consistently, MG1131 is bound to TIGIT-expressing cells and interferes with PVR binding to these cells.	mg1131	14-20	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	33-38
34030043-0	2021	The N-linked glycosylations of TIGIT Asn32 and Asn101 facilitate PVR/TIGIT interaction.	Nitrogen	4-5	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	31-36
34030043-0	2021	The N-linked glycosylations of TIGIT Asn32 and Asn101 facilitate PVR/TIGIT interaction.	Nitrogen	4-5	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	69-74
34030043-2	2021	Here we show that TIGIT N-glycosylations are critical for maintaining the interaction between TIGIT and PVR.	Nitrogen	24-25	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	18-23
34030043-2	2021	Here we show that TIGIT N-glycosylations are critical for maintaining the interaction between TIGIT and PVR.	Nitrogen	24-25	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	94-99
34030043-3	2021	TIGIT has two N-glycosylation residues, N32 and N101.	Nitrogen	14-15	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	0-5
34030043-4	2021	N-glycosylation on N101 of TIGIT and, to less extent, on N32, play potent roles in PVR binding.	Nitrogen	0-1	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	27-32
34030043-4	2021	N-glycosylation on N101 of TIGIT and, to less extent, on N32, play potent roles in PVR binding.	1,3-Dibutylxanthine	19-23	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	27-32
34030043-5	2021	Taken together, these findings suggest that the N-glycosylation sites on TIGIT, especially residue N101, may be potential targets for PVR/TIGIT immune checkpoint blockade.	Nitrogen	48-49	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	73-78
34030043-5	2021	Taken together, these findings suggest that the N-glycosylation sites on TIGIT, especially residue N101, may be potential targets for PVR/TIGIT immune checkpoint blockade.	Nitrogen	48-49	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	138-143
34030043-5	2021	Taken together, these findings suggest that the N-glycosylation sites on TIGIT, especially residue N101, may be potential targets for PVR/TIGIT immune checkpoint blockade.	1,3-Dibutylxanthine	99-103	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	73-78
34030043-5	2021	Taken together, these findings suggest that the N-glycosylation sites on TIGIT, especially residue N101, may be potential targets for PVR/TIGIT immune checkpoint blockade.	1,3-Dibutylxanthine	99-103	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	138-143
33903974-7	2021	We explored the therapeutic potential of targeting TIGIT by generating COM902, a fully human anti-TIGIT hinge-stabilized IgG4 monoclonal antibody that binds specifically to human, cynomolgus monkey, and mouse TIGIT, and disrupts the binding of TIGIT with PVR.	com902	71-77	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	51-56
33933849-0	2021	Artesunate-induced ATG5-related autophagy enhances the cytotoxicity of NK92 cells on endometrial cancer cells via interactions between CD155 and CD226/TIGIT.	Artesunate	0-10	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	151-156
33933849-6	2021	Meanwhile, ART-induced autophagy elevated the level of CD155 in UCEC cells, thereby enhancing the cytotoxicity of natural killer cell line (NK92) by modulating the interactions between CD155 and its receptors in NK92 cells via upregulation of co-stimulator CD226 and downregulation of co-inhibitor TIGIT.	Artesunate	11-14	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	298-303
33903974-7	2021	We explored the therapeutic potential of targeting TIGIT by generating COM902, a fully human anti-TIGIT hinge-stabilized IgG4 monoclonal antibody that binds specifically to human, cynomolgus monkey, and mouse TIGIT, and disrupts the binding of TIGIT with PVR.	com902	71-77	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	98-103
33670993-4	2021	T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) has received considerable attention in cancer immunotherapy.	Tyrosine	49-57	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	97-102
33855917-3	2021	T-cell immunoglobulin, as well as immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT)/CD155 pathway, possesses critical parts in the development of normal pregnancy by promoting regulatory T (Treg) cells.	Tyrosine	49-57	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	96-101
32810392-8	2020	Oxysophocarpine sensitized the Lag-3 immunotherapy effect of CD8+ T cells against HCC in vivo and in vitro by decreasing Fibrinogen-like protein 1 (FGL1) expression through downregulating IL-6-mediated JAK2/STAT3 signaling, whereas Oxysophocarpine treatment had a little effect of CD8+ T cells cytotoxicity function against HCC with PD-1, Tim-3, or TIGIT blockade.	oxysophocarpine	0-15	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	349-354
33341068-4	2021	In this article, we describe a novel anti-TIGIT monoclonal antibody, AET2010, which was acquired from a phage-displayed human single-chain antibody library through a cell panning strategy.	aet2010	69-76	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	42-47
32804915-3	2020	T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is an immune inhibitory receptor expressed by regulatory T cells and activated T cells and natural killer cells.	Tyrosine	41-49	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	81-86
31862674-0	2020	Carboplatin chemoresistance is associated with CD11b+/Ly6C+ myeloid release and upregulation of TIGIT and LAG3/CD160 exhausted T cells.	Carboplatin	0-11	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	96-101
32386245-3	2020	Here, mirror-image phage display bio-panning was performed using the D-enantiomer of TIGIT synthesized by hydrazide-based native chemical ligation.	hydrazide	106-115	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	85-90
32265229-5	2020	Anti-TIGIT treatment selectively affects CD226hiCD8+ T cells by promoting CD226 phosphorylation at tyrosine 322.	Tyrosine	99-107	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	5-10
32265229-7	2020	Finally, mFOLFIRINOX treatment, which increases CD226hiCD8+ T cells in patients with pancreatic ductal adenocarcinoma, potentiates the effects of TIGIT or PD-1 blockade.	mfolfirinox	9-20	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	146-151
32122675-2	2020	T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) and programmed cell death protein 1 (PD-1) are identified to be abnormally overexpressed in various types of cancers including GC.	Tyrosine	41-49	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	88-93
31090213-9	2019	In this paper, we found that aspirin attenuates cancer cell proliferation and induces CRC cells apoptosis by down-regulating the expression of TIGIT, which provides new evidence for the application of aspirin in cancer treatment.	Aspirin	29-36	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	143-148
31090213-9	2019	In this paper, we found that aspirin attenuates cancer cell proliferation and induces CRC cells apoptosis by down-regulating the expression of TIGIT, which provides new evidence for the application of aspirin in cancer treatment.	Aspirin	201-208	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	143-148
31090213-0	2019	Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway.	Aspirin	7-14	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	62-67
30633591-7	2019	The expressions of co-inhibitory receptors (CTLA-4, PD-1, Tim-3, LAG-3 and TIGIT) on Tregs in FK506 + MMF group were significant higher than those in the FK506 group and control group.	Tacrolimus	94-99	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	75-80
31090213-8	2019	We found that the expression of TIGIT decreased with an increase in the concentration of aspirin and that the suppression of TIGIT can affect the effect of aspirin on cell proliferation.	Aspirin	89-96	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	32-37
31090213-8	2019	We found that the expression of TIGIT decreased with an increase in the concentration of aspirin and that the suppression of TIGIT can affect the effect of aspirin on cell proliferation.	Aspirin	156-163	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	32-37
31090213-8	2019	We found that the expression of TIGIT decreased with an increase in the concentration of aspirin and that the suppression of TIGIT can affect the effect of aspirin on cell proliferation.	Aspirin	156-163	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	125-130
30633591-7	2019	The expressions of co-inhibitory receptors (CTLA-4, PD-1, Tim-3, LAG-3 and TIGIT) on Tregs in FK506 + MMF group were significant higher than those in the FK506 group and control group.	Mycophenolic Acid	102-105	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	75-80
30382432-3	2019	Our previous study showed that T cell immunoglobulin and immunoreceptor tyrosine-based inhibition motif (ITIM) domain (TIGIT) plays a critical role in regulating CD4 + T cell functions.	Tyrosine	72-80	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	119-124
29890552-7	2019	RESULTS: The TIGIT and FCRL3 expression levels from T cells of AT cases were inversely related to the thyroid volume, and were significantly increased in hypothyroid patients (on+off L-thyroxine), but not euAT cases.	Thyroxine	183-194	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	13-18
30402886-1	2019	The T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory receptor mainly expressed on T cells.	Tyrosine	45-53	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	85-90
30713804-9	2019	In comparison, we found that CTLA-4, TIM-3, TIGIT and PD-L1 in PBC, and CTLA-4 in CRC patients were significantly upregulated in peripheral blood, compared with tumor tissues of the same patients.	potassium bicarbonate	63-66	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	44-49
30713804-10	2019	However, demethylation status of all ICs was higher in TT, except for TIGIT in PBC, and CTLA-4 in CRC patients.	potassium bicarbonate	79-82	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	70-75
29147616-10	2017	In MIBC, a molecular signature of 3 genes (OX40L, CD8 and TIGIT) was significantly associated with prognosis in terms of recurrence-free and overall survival (p = 0.0007 and p = 0.007).	4-METHYL-2-PENTANOL	3-7	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	58-63
29512870-5	2018	Blockade of T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains (TIGIT) using a neutralizing antibody also selectively inhibited Th2 cell responses.	Tyrosine	73-81	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	114-119
29512870-9	2018	These findings suggest that DW2008S can potentially ameliorate Th2-driven airway inflammation and bronchoconstriction through negative regulation of TIGIT and blockade of A3 AR and PDE4 activities.	dw2008s	28-35	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	149-154
30179225-9	2018	APC with dMMR mutational signatures overexpressed a variety of immune transcripts, including CD200R1, BTLA, PD-L1, PD-L2, ADORA2A, PIK3CG, and TIGIT.	dmmr	9-13	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	143-148
28629373-1	2017	BACKGROUND: T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) and programmed cell death protein 1 (PD-1) are important inhibitory receptors that associate with T cell exhaustion in acute myeloid leukemia (AML).	Tyrosine	53-61	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	100-105
26250578-3	2015	Here we show that a previously unidentified subset of human circulating T follicular helper cells expressing TIGIT, the T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory domains, exhibit strong B-cell help functions.	Tyrosine	169-177	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	109-114
26683997-3	2016	In this study, we investigated the role of T cell immunoglobulin and ITIM (immunoreceptor tyrosine-based inhibition motif) domain (TIGIT) in RA.	Tyrosine	90-98	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	131-136
26683997-6	2016	In CD4(+) T cells isolated from SF of active RA patients, TIGIT upregulation significantly decreased cell proliferation, as shown by MTT assay.	monooxyethylene trimethylolpropane tristearate	133-136	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	58-63
28282368-0	2017	Elevated Expression of Immunoreceptor Tyrosine-Based Inhibitory Motif (TIGIT) on T Lymphocytes is Correlated with Disease Activity in Rheumatoid Arthritis.	Tyrosine	38-46	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	71-76
28282368-2	2017	T cell immunoreceptors with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (TIGIT) have immunosuppressive co-stimulatory molecules that mediate inhibitory effects, but their roles in RA are poorly understood.	Tyrosine	67-75	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	100-105
26482547-10	2015	Collectively, our data provide the groundwork for dissecting the effect of DAA therapy on the immune system and identifying novel mechanisms by which chronic HCV infection exerts immunosuppressive effects on T cells through the recently described co-inhibitory molecule TIGIT.	daa	75-78	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	270-275
23974203-9	2013	In support of the view that methylation limits access of FOXP3 to its DNA targets, we showed that increased expression of the immune suppressive receptor T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT), which delineated Treg from activated effector T cells, was associated with hypomethylation and FOXP3 binding at the TIGIT locus.	Tyrosine	195-203	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	235-240
24905442-2	2014	T cell immunoglobulin and ITIM (immunoreceptor tyrosine-based inhibition motif) domain (TIGIT) is an inhibitory receptor, which exhibits inhibitory functions on the immune response.	Tyrosine	47-55	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	88-93
23974203-9	2013	In support of the view that methylation limits access of FOXP3 to its DNA targets, we showed that increased expression of the immune suppressive receptor T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT), which delineated Treg from activated effector T cells, was associated with hypomethylation and FOXP3 binding at the TIGIT locus.	Tyrosine	195-203	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	359-364
23154388-2	2013	T-cell immunoglobulin and ITIM (immunoreceptor tyrosine-based inhibition motif) domain (TIGIT) was recently identified as a new inhibitory receptor on T and NK cells that suppressed their effector functions.	Tyrosine	47-55	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	88-93
23154388-3	2013	TIGIT harbors the immunoreceptor tail tyrosine (ITT)-like and ITIM motifs in its cytoplasmic tail.	Tyrosine	38-46	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	0-5
23154388-3	2013	TIGIT harbors the immunoreceptor tail tyrosine (ITT)-like and ITIM motifs in its cytoplasmic tail.	Inosine Triphosphate	48-51	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	0-5
19011627-1	2009	Here we have identified a surface protein, TIGIT, containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif that was expressed on regulatory, memory and activated T cells.	Tyrosine	141-149	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	43-48